Bernstein has upgraded Beam Therapeutics (BEAM) to outperform, citing upcoming data on the company’s drug candidate for AATD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback